Your Global Leader in Stem Cell Market Research
The history of cord blood and tissue banking dates back to the early 1990’s when three private cord blood banks were formed within the United States. These banks were Cord Blood Registry, Cryo-Cell, and Viacord, all of which are AABB accredited banks. Shortly thereafter, cord blood banks began forming in leading healthcare markets worldwide.
In this article:
Currently, it costs a public bank approximately USD $2,000 to collect, test, and process a unit of cord blood for storage. In order to accept donations at no cost, public banks require income to support themselves. This income can come from federal funding, the profit margin of private banking, or from selling donated cord blood units for research. Alternatively, it can come from a combination of the above.
Over the past 30 years, cord blood and cord tissue have gained popularity and commercial traction due to the valuable stem cells they contain. According to ClinicalTrials.gov, there are over 1,360 clinical trials evaluating the use of cord blood and tissue-derived cells. These studies typically leverage unmanipulated whole cord blood (total nucleated cells/TNC), mononuclear cells (MNC), or cord blood-derived mesenchymal stem cells (MSCs). [Read more…]
NEW YORK, NEW YORK, US, October 11, 2022 – Americord Registry®, a leader in the cord blood industry, announced the addition of exosome banking to their suite of family-focused services, becoming the first private biobanking company in the United States to do so. Exosomes are tiny, extracellular vesicles that initiate cell-to-cell communication by shuttling cellular components to other cells. Pre-clinical research has shown that exosomes may regulate immune responses, wound healing, and cell growth and development. [Read more…]
In this interview with Dr. Ornella Parolini, Director of the E. Menni Research Center in Italy, we discussed her pioneering research on human placental stem cells. Her research is focused on the immunomodulatory and anti-inflammatory properties of amniotic and chorionic membrane cells. She is also President of the International Placenta Stem Cell Society (IPLASS), making her a globally recognized expert.
In addition to Dr. Robert Harari who holds a wide range of placental stem cell patents, Dr. Parolini is one of the world’s leading experts on placental stem cells and their therapeutic applications.
In this article:
